A total of 32 interactions were observed between 32 small-molecule drugs and 4 pleiotropic genes (MAP3K8, EGR2, PIM3, and SMAD3), which may represent novel therapeutic targets for IBD. Here, MAP3K8 is linked to inflammatory bowel disease.